CN Patent

CN116735877A — Hdgf作为酪氨酸激酶抑制剂耐药靶点及相关应用

Assigned to Beijing Cancer Hospital · Expires 2023-09-12 · 3y expired

What this patent protects

本发明提供了肝癌衍生生长因子HDGF作为酪氨酸激酶抑制剂耐药靶点及相关应用。本发明提供了肝癌衍生生长因子HDGF作为靶点在筛选和/或制备具有改善患者对酪氨酸激酶抑制剂耐药作用的药物中的应用。本发明发现HDGF高表达是分子靶向药吉非替尼等酪氨酸激酶抑制剂耐药的机制之一。以HDGF为靶点可有效改善NSCLC对吉非替尼的耐药，提高疗效。

USPTO Abstract

本发明提供了肝癌衍生生长因子HDGF作为酪氨酸激酶抑制剂耐药靶点及相关应用。本发明提供了肝癌衍生生长因子HDGF作为靶点在筛选和/或制备具有改善患者对酪氨酸激酶抑制剂耐药作用的药物中的应用。本发明发现HDGF高表达是分子靶向药吉非替尼等酪氨酸激酶抑制剂耐药的机制之一。以HDGF为靶点可有效改善NSCLC对吉非替尼的耐药，提高疗效。

Drugs covered by this patent

Patent Metadata

Patent number
CN116735877A
Jurisdiction
CN
Classification
—
Expires
2023-09-12
Drug substance claim
No
Drug product claim
No
Assignee
Beijing Cancer Hospital
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.